


# Stabilis



## Ranitidine hydrochloride



Noms commerciaux

Acloral	Mexique
Antak	
Azantac	
B-Alcerin	
Coralen	
Epadoren	Grèce
Histac	
Logat	
Lumaren	Grèce
Pep rani	
Peptoran	
Ptinolin	Grèce
Ranic	
Ranidil	Italie
Ranigast	Pologne
Ranisan	
Ranitab	Turquie
Ranital	
Ranitic	Allemagne
Ranitidin	Allemagne
Rantag	Allemagne
Rinavian	Argentine
Solvertyl	
Stacer	
Taural	
Ulcuran	Turquie
Ulsal	Autriche
Zantac	Belgique, Danemark, Espagne, Etats Unis d'Amérique, Grande Bretagne, Grèce, Italie, Norvège, Pays bas, Portugal, Suède, Thaïlande, Turquie
Zantic	Suisse
Zydac	Arabie Saoudite
Zylium	Brésil



## Stabilité des solutions

		2,5 mg/ml	4°C		91			46
PVC		0,05 mg/ml	20°C-25°C		7			213
PVC		0,5 & 1 mg/ml	-30°C		30			358
PVC		0,5 & 1 & 2 mg/ml	-20°C		60			78
PVC		0,5 & 1 & 2 mg/ml	25°C		7			78
PVC		0,5 & 1 & 2 mg/ml	4°C		30			78
PVC		0,5 >> 2 mg/ml	20°C-25°C		28			213
PVC		1 mg/ml	25°C		15			693
PVC		1 mg/ml	4°C		10			358
PVC		1 mg/ml	4°C		92			689
PVC		1 mg/ml	5°C		63			693
PVC		2 mg/ml	-30°C		100			358
PVC		0,05 mg/ml	20°C-25°C		2			213
PVC		0,5 & 1 & 2 mg/ml	-20°C		60			78
PVC		0,5 & 1 & 2 mg/ml	25°C		7			78
PVC		0,5 & 1 & 2 mg/ml	4°C		30			78
PE		0,25 mg/ml	22°C		24			1067
PE		0,25 mg/ml	4°C		24			1067
PE		5 mg/ml	25°C		91			4131
PE		5 mg/ml	5°C		91			4131
PE		2,5 mg/ml	22°C		72			46
PE		2,5 mg/ml	4°C		91			46




## Stabilité en mélange

		0,5 mg/ml	23°C		Aztreonam : 8,6 mg/ml	4		360
		0,5 mg/ml	23°C		Ceftazidime : 10 mg/ml	4		360
		1 mg/ml	22°C-23°C		Cefmetazole sodium : 20 mg/ml	2		903
		0,5 mg/ml	22°C-23°C		Aztreonam : 8,6 mg/ml	4		360

		0,5 mg/ml	22°C-23°C		Ceftazidime : 10 mg/ml	4		360
		0,5 mg/ml	22°C-23°C		Piperacillin sodium : 15 mg/ml	4		360
		1 mg/ml	22°C-23°C		Cefmetazole sodium : 10 mg/ml	4		903
		0,5 & 2 mg/ml	23°C		Piperacillin sodium / tazobactam : 80/10 mg/ml	4		235
		0,5 mg/ml	25°C		Moxalactam : 10 mg/ml	2		934
		0,5 mg/ml	25°C		Ceftizoxime sodium : 10 mg/ml	4		934
		0,5 mg/ml	25°C		Cefoperazone sodium : 10 mg/ml	4		934
		0,5 mg/ml	25°C		Cefmenoxime : 10 mg/ml	4		934
		0,5 mg/ml	25°C		Cefuzonam : 10 mg/ml	4		934
		0,5 mg/ml	25°C		Cefazolin sodium : 20 mg/ml	4		2355
		0,6 mg/ml	20°C-25°C		Labetalol hydrochloride : 1 mg/ml	4		199
		0,85 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		0,5 & 2 mg/ml	23°C		Paclitaxel : 0,3 & 1,2 mg/ml	4		47
		2,0 mg/ml	23°C		Paclitaxel : 1,2 mg/ml Ondansetron hydrochloride : 0,3 mg/ml	4		47
		0,5 & 2 mg/ml	25°C		Ondansetron hydrochloride : 0,03 & 0,3 mg/ml	4		18
		0,5 mg/ml	23°C		Zidovudine : 2 mg/ml	24		1900
		0,5 mg/ml	4°C		Zidovudine : 2 mg/ml	24		1900
		0,05 & 2 mg/ml	?		Aminophylline : 0,5 & 2 mg/ml	48		210
		0,05 & 2 mg/ml	?		Lidocaine hydrochloride : 1 & 8 mg/ml	48		210
		0,05 & 2 mg/ml	?		Dobutamine hydrochloride : 0,25 & 1 mg/ml	48		210
		0,05 & 2 mg/ml	?		Nitroprusside sodium : 0,05 & 0,4 mg/ml	48		210
		0,05 & 2 mg/ml	?		Dopamine hydrochloride : 0,4 & 3,2 mg/ml	48		210
		1 mg/ml	25°C		Insulin : 1 UI/ml	1		208
		0,05 mg/ml	?		Methylprednisolone sodium succinate : 0,04 mg/ml	24		210
		0,05 & 2 mg/ml	?		Methylprednisolone sodium succinate : 2 mg/ml	24		210
		2 mg/ml	?		Methylprednisolone sodium succinate : 0,04 mg/ml	48		210
		0,3 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24		187
		2 mg/ml	?		Norepinephrine bitartrate : 0,004 mg/ml	4		210
		2 mg/ml	?		Norepinephrine bitartrate : 0,008 mg/ml	12		210
		0,05 mg/ml	?		Norepinephrine bitartrate : 0,004 & 0,008 mg/ml	48		210
		0,05 & 2 mg/ml	?		Methylprednisolone sodium succinate : 0,04 & 2 mg/ml	48		210



## Compatibilités

			
	Ranitidine hydrochloride : 1 mg/ml Aciclovir sodium : 5 mg/ml		336
	Ranitidine hydrochloride : 1 mg/ml Aldesleukin : 0.0338 MUI/ml		36
	Ranitidine hydrochloride : 2 mg/ml Allopurinol sodium : 3 mg/ml		307
	Ranitidine hydrochloride : 2 mg/ml Amifostine : 10 mg/ml		3
	Ranitidine hydrochloride : 0,5 mg/ml Aminophylline : 4 mg/ml		396
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Aminophylline : 0.5 & 2 mg/ml		210
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Aminophylline : 0.5 & 2 mg/ml		214
	 Ranitidine hydrochloride : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml		921
	Ranitidine hydrochloride : 2 mg/ml Amsacrine : 1 mg/ml		253
	Ranitidine hydrochloride : 2 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Ranitidine hydrochloride : 0.5 mg/ml Atracurium besylate : 0.5 mg/ml		402
	Ranitidine hydrochloride : 25 mg/ml Atropine sulfate : 0,4 mg/ml		58
	Ranitidine hydrochloride : 2 mg/ml Aztreonam : 40 mg/ml		99
	Ranitidine hydrochloride : 2 mg/ml Bivalirudin : 5 mg/ml		1713
	Ranitidine hydrochloride : 0,5 mg/ml Bretylum tosilate : 4 mg/ml		396
	Ranitidine hydrochloride : 25 mg/ml Caffeine : 10 mg/ml		3964
	Ranitidine hydrochloride : 1 mg/ml Cefalotin sodium : 10 mg/ml		2355
	 Ranitidine hydrochloride : 1 mg/ml Cefalotin sodium : 20 mg/ml		2355
	Ranitidine hydrochloride : 1 mg/ml Cefazolin sodium : 20 mg/ml		2355
	Ranitidine hydrochloride : 2,5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
	Ranitidine hydrochloride : 1 mg/ml Cefmenoxime : 20 mg/ml		934
	 Ranitidine hydrochloride : 1 mg/ml Cefmetazole sodium : 10 & 20 mg/ml		903
	Ranitidine hydrochloride : 1 mg/ml Cefoperazone sodium : 20 mg/ml		934
	Ranitidine hydrochloride : 1 mg/ml Cefoxitin sodium : 20 mg/ml		2355

	Ranitidine hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Ranitidine hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Ranitidine hydrochloride : 1 mg/ml Ceftizoxime sodium : 20 mg/ml		934
	Ranitidine hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Ranitidine hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Ranitidine hydrochloride : 2.5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	Ranitidine hydrochloride : 1 mg/ml Cefuzonam : 20 mg/ml		934
	Ranitidine hydrochloride : 25 mg/ml Chlorpromazine hydrochloride : 25 mg/ml	∅	58
	Ranitidine hydrochloride : 2 mg/ml Ciprofloxacin lactate : 2 mg/ml		289
	Ranitidine hydrochloride : 0.5 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
	Ranitidine hydrochloride : 0,5 mg/ml Ciprofloxacin lactate : 2 mg/ml		289
	Ranitidine hydrochloride : 2 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Ranitidine hydrochloride : 2 mg/ml Cladribine : 0.015 mg/ml		1496
	Ranitidine hydrochloride : 2 mg/ml Cladribine : 0.5 mg/ml		1496
	Ranitidine hydrochloride Clindamycin phosphate		3526
	Ranitidine hydrochloride : 25 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Ranitidine hydrochloride : 25 mg/ml Cyclizine lactate : 50 mg/ml	∅	58
	Ranitidine hydrochloride : 2 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Ranitidine hydrochloride : 25 mg/ml Diazepam : 10 mg/ml	∅	58
	Ranitidine hydrochloride : 1 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
	Ranitidine hydrochloride : 25 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
	Ranitidine hydrochloride : 0.5 & 1 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Ranitidine hydrochloride : 25 mg/ml Dimenhydrinate : 50 mg/ml	∅	58
	Ranitidine hydrochloride : 25 mg/ml Diphenhydramine hydrochloride : 50 mg/ml	∅	58
	Ranitidine hydrochloride : 1 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Dobutamine hydrochloride : 0.25 & 1 mg/ml		210

	Ranitidine hydrochloride : 0.05 & 2 mg/ml Dobutamine hydrochloride : 0.25 & 1 mg/ml		214
	Ranitidine hydrochloride : 0,5 mg/ml Dobutamine hydrochloride : 1 mg/ml		396
	Ranitidine hydrochloride : 2 mg/ml Docetaxel : 0.9 mg/ml		1754
	Ranitidine hydrochloride : 0,5 mg/ml Dopamine hydrochloride : 1,6 mg/ml		396
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Dopamine hydrochloride : 0.4 & 3.2 mg/ml		210
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Dopamine hydrochloride : 0.4 & 3.2 mg/ml		214
	Ranitidine hydrochloride : 1 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Ranitidine hydrochloride : 2 mg/ml Doripenem : 5 mg/ml		2262
	Ranitidine hydrochloride : 2 mg/ml Doxapram hydrochloride : 2 mg/ml		1802
	Ranitidine hydrochloride : 2 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Ranitidine hydrochloride : 0.5 mg/ml Enalaprilate : 0.0125 mg/ml		1703
	Ranitidine hydrochloride : 0.5 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Ranitidine hydrochloride : 1 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
	Ranitidine hydrochloride : 0,5 mg/ml Esmolol hydrochloride : 10 mg/ml		384
	Ranitidine hydrochloride : 2 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Ranitidine hydrochloride : 2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Ranitidine hydrochloride : 25 mg/ml Fentanyl citrate : 50 µg/ml		58
	Ranitidine hydrochloride : 1 mg/ml Fentanyl citrate : 50 µg/ml		314
	Ranitidine hydrochloride : 2 mg/ml Filgrastim : 30 µg/ml		244
	Ranitidine hydrochloride : 0,5 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
	Ranitidine hydrochloride : 0,5 & 2 mg/ml Fluconazole : 2 mg/ml		18
	Ranitidine hydrochloride : 2 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Ranitidine hydrochloride : 0,3 mg/ml Flumazenil : 0,02 mg/ml		187
	Ranitidine hydrochloride : 2 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Ranitidine hydrochloride : 2.5 mg/ml Fosfomycin : 30 mg/ml		4055
	Ranitidine hydrochloride : 1 mg/ml Furosemide : 10 mg/ml		314



<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0,5 mg/ml Furosemide : 1 mg/ml		1232	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2,5 mg/ml Gallium nitrate : 1 mg/ml		91	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 25 mg/ml Glycopyrronium bromide : 0,2 mg/ml		58	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 1 mg/ml Heparin sodium : 50 UI/ml		317	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.05 & 2 mg/ml Heparin sodium : 10 & 40 UI/ml		214	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 1 mg/ml Heparin sodium : 100 UI/ml		314	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0,5 mg/ml Heparin sodium : 50 UI/ml		396	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2 mg/ml Hetastarch : 60 mg/ml		1721	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.5 mg/ml Hetastarch : 60 mg/ml		472	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 25 mg/ml Hydromorphone hydrochloride : 2 mg/ml		58	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 1 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 1 mg/ml Idarubicin hydrochloride : 1 mg/ml		491	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2.5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 25 mg/ml Ketamine hydrochloride : 50 mg/ml		2109	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.15 mg/ml		1987	
	<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.5 mg/ml Hetastarch : 60 mg/ml		465
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 25 mg/ml Hydroxyzine dihydrochloride : 50 mg/ml		58	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2,5 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.05 & 0.1 mg/ml		209	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 1 mg/ml Ketoprofene : 3.2 mg/ml		1847	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.05 & 0.1 mg/ml		359	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.08 >> 0.25 mg/ml		1248	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 25 mg/ml		316	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 0.6 mg/ml Labetalol hydrochloride : 1 mg/ml		199	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2.5 mg/ml		939	
<input checked="" type="checkbox"/>	Ranitidine hydrochloride : 2 mg/ml		301	

		Ranitidine hydrochloride : 1 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Ranitidine hydrochloride : 0.5 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Ranitidine hydrochloride : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Ranitidine hydrochloride : 25 mg/ml Levomepromazine : 25 mg/ml		58
		Ranitidine hydrochloride : 0.05 & 2 mg/ml Lidocaine hydrochloride : 1 & 8 mg/ml		210
		Ranitidine hydrochloride : 2 mg/ml Linezolid : 2 mg/ml		1925
		Ranitidine hydrochloride : 25 mg/ml Lorazepam : 4 mg/ml		58
		Ranitidine hydrochloride : 0.049 >> 0.067 mg/ml		1868
		Ranitidine hydrochloride : 2 mg/ml		1415
		Ranitidine hydrochloride : 0.05 & 0.1 mg/ml		209
		Ranitidine hydrochloride : 0.05 & 0.1 mg/ml		357
		Ranitidine hydrochloride : 25 mg/ml	<b>RL</b>	4603
		Ranitidine hydrochloride : 0.05 & 2 mg/ml Lidocaine hydrochloride : 1 & 8 mg/ml		214
		Ranitidine hydrochloride : 0.5 mg/ml Lorazepam : 0.33 mg/ml		186
		Ranitidine hydrochloride : 1 mg/ml Lorazepam : 0.5 mg/ml		314
		Ranitidine hydrochloride : 2 mg/ml Melphalan : 0.1 mg/ml		169
		Ranitidine hydrochloride : 0.1 mg/ml Meropenem : 1 & 20 mg/ml		266
		Ranitidine hydrochloride : 25 mg/ml Meropenem : 50 mg/ml		4319
		Ranitidine hydrochloride Methotrexate sodium		3637
		Ranitidine hydrochloride : 0.05 & 2 mg/ml Methylprednisolone sodium succinate : 0.04 & 2 mg/ml		210
		Ranitidine hydrochloride : 25 mg/ml Metoclopramide hydrochloride : 10 mg/ml		58
		Ranitidine hydrochloride : 1 mg/ml Metoclopramide hydrochloride : 0,2 mg/ml		3558
		Ranitidine hydrochloride : 0.5 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Ranitidine hydrochloride : 16.67 mg/ml Midazolam hydrochloride : 1.67 mg/ml		404
		Ranitidine hydrochloride : 1 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Ranitidine hydrochloride : 0.4 mg/ml Midazolam hydrochloride : 0.05 & 0.25 mg/ml		1888
		Ranitidine hydrochloride : 1 mg/ml Milrinone lactate : 0.2 mg/ml		314



	Ranitidine hydrochloride : 4 mg/ml Milrinone lactate : 0.8 mg/ml		813
	Ranitidine hydrochloride : 16.67 mg/ml Morphine hydrochloride : 1.67 >> 10 mg/ml		1757
	Ranitidine hydrochloride : 1 mg/ml Morphine sulfate : 2 mg/ml		314
	Ranitidine hydrochloride : 0.5 mg/ml Morphine sulfate : 1 mg/ml		406
	Ranitidine hydrochloride : 25 mg/ml Morphine sulfate : 10 mg/ml		58
	Ranitidine hydrochloride : 1 mg/ml Moxalactam : 20 mg/ml		934
	Ranitidine hydrochloride : 25 mg/ml N-acetylcysteine : 200 mg/ml		3766
	Ranitidine hydrochloride : 25 mg/ml Nalbuphine hydrochloride : 10 mg/ml		58
	Ranitidine hydrochloride : 25 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Ranitidine hydrochloride : 0,5 mg/ml Netilmicin sulfate : 1 mg/ml		958
	Ranitidine hydrochloride : 1 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
	Ranitidine hydrochloride : 0.5 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Ranitidine hydrochloride : 1 mg/ml Nitroglycerin : 0.4 mg/ml		314
	Ranitidine hydrochloride : 0,5 mg/ml Nitroglycerin : 0,2 mg/ml		396
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Nitroprusside sodium : 0.05 & 0.4 mg/ml		214
	Ranitidine hydrochloride : 1 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Norepinephrine bitartrate : 4 & 8 mg/ml		214
	Ranitidine hydrochloride : 0.05 & 2 mg/ml Norepinephrine bitartrate : 0.004 & 0.008 mg/ml		210
	Ranitidine hydrochloride : 2 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Ranitidine hydrochloride : 0,5 & 2 mg/ml Ondansetron hydrochloride : 0,03 >> 0,3 mg/ml		18
	Ranitidine hydrochloride : 2 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
	Ranitidine hydrochloride : 2 mg/ml Oxaliplatin : 0,5 mg/ml		1662
	Ranitidine hydrochloride : 0.5 & 2 mg/ml Paclitaxel : 0.3 & 1.2 mg/ml		47
	Ranitidine hydrochloride : 2 mg/ml Paclitaxel : 1.2 mg/ml		85
	Ranitidine hydrochloride : 0.5 mg/ml Pancuronium bromide : 0.05 mg/ml		402
	Ranitidine hydrochloride Pantoprazole sodium		2090

		Ranitidine hydrochloride : 1 mg/ml Paracetamol : 10 mg/ml	∅	3571
		Ranitidine hydrochloride : 2 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
		Ranitidine hydrochloride : 1.2 & 2 mg/ml Pethidine hydrochloride : 10 mg/ml	▲	406
		Ranitidine hydrochloride : 25 mg/ml Pethidine hydrochloride : 100 mg/ml	∅	58
		Ranitidine hydrochloride : 0.5 mg/ml Pethidine hydrochloride : 10 mg/ml	▲	406
		Ranitidine hydrochloride : 25 mg/ml Phenobarbital sodium : 120 mg/ml	∅	58
		Ranitidine hydrochloride : 2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
		Ranitidine hydrochloride : 2.5 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
		Ranitidine hydrochloride : 0.05 & 2 mg/ml Potassium chloride : 10 & 60 mEq/l	▲◆	214
		Ranitidine hydrochloride : 0,5 mg/ml Procainamide hydrochloride : 4 mg/ml	◆	396
		Ranitidine hydrochloride : 25 mg/ml Prochlorperazine edysilate : 5 mg/ml	∅	58
		Ranitidine hydrochloride : 25 mg/ml Promethazine hydrochloride : 25 mg/ml	∅	58
		Ranitidine hydrochloride : 2 mg/ml Propofol : 10 mg/ml	∅	300
		Ranitidine hydrochloride : 25 mg/ml Propofol		660
		Ranitidine hydrochloride : 25 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Ranitidine hydrochloride : 2 mg/ml Sargramostim : 10 µg/ml	▲	335
		Ranitidine hydrochloride : 25 mg/ml Scopolamine hydrobromide : 0,4 mg/ml	∅	58
		Ranitidine hydrochloride Sugammadex		2328
		Ranitidine hydrochloride : 25 mg/ml Tacrolimus : 1000 µg/ml	▲	479
		Ranitidine hydrochloride : 2.5 mg/ml Tedizolid phosphate : 0.8 mg/ml	▲	3827
		Ranitidine hydrochloride : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Ranitidine hydrochloride : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml	▲◆	3254
		Ranitidine hydrochloride : 2.5 mg/ml Temocilline : 83.33 mg/ml	💧	2231
		Ranitidine hydrochloride Temocilline		4470
		Ranitidine hydrochloride : 2 mg/ml Teniposide : 0.1 mg/ml	◆	905
		Ranitidine hydrochloride : 1 mg/ml Theophylline : 4 mg/ml	∅	317

		Ranitidine hydrochloride : 25 mg/ml Thiopental sodium : 25 mg/ml		3767
		Ranitidine hydrochloride : 1 mg/ml Thiopental sodium : 25 mg/ml		314
		Ranitidine hydrochloride : 20 mg/ml Thiotepa : 1 mg/ml		249
		Ranitidine hydrochloride Tigecycline		3332
		Ranitidine hydrochloride : 0,5 mg/ml Tramadol hydrochloride : 0,4 mg/ml		2002
		Ranitidine hydrochloride : 25 mg/ml Valproic acid : 2 & 20 mg/ml		4428
		Ranitidine hydrochloride : 0.5 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Ranitidine hydrochloride : 1 mg/ml Vecuronium bromide : 1 mg/ml		314
		Ranitidine hydrochloride : 2 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Ranitidine hydrochloride : 1 mg/ml Warfarin sodium : 2 mg/ml		315
		Ranitidine hydrochloride : 1 mg/ml Zidovudine : 4 mg/ml		337



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
18	Revue	Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA. Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 391-394.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
46	Revue	Nahata MC, Morosco RS, Fox JL. Stability of ranitidine hydrochloride in water for injection in glass vials and plastic syringes. Am J Health-Syst Pharm 1996 ; 53: 1588-1590.
47	Revue	Burm JP, Jhee SS, Chin A, Moon YSK. Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration. Am J Hosp Pharm 1994 ; 51: 1201-1204.

58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
78	Revue	Stewart JT, Warren FW, Johnson SM, Galante LJ. Stability of ranitidine in intravenous admixtures stored frozen, refrigerated, and at room temperature. Am J Hosp Pharm 1990 ; 47: 2043-2046.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Revue	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
187	Revue	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
199	Revue	Hassan E, Leslie J, Martir-Herrero ML. Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 2143-2145.
208	Revue	Nolan PE, Hoyer GL, Ledoux JH, Fox JL. Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1997 ; 54: 1304-1306.
209	Revue	Williams MF, Hak LJ, Dukes G. In vitro evaluation of the stability of ranitidine hydrochloride in total parenteral nutrient mixtures. Am J Hosp Pharm 1990 ; 47: 1574-1579.
210	Revue	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
213	Revue	Galante LJ, Stewart JT, Warren FW, Johnson SM, Duncan R. Stability of ranitidine hydrochloride at dilute concentration in intravenous infusion fluids at room temperature. Am J Hosp Pharm 1990 ; 47: 1580-1584.

214	Revue	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
235	Revue	Choi JS, Burm JP, Jhee SS, Chin A, Ulrich RW, Gill MA. Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 2273-2276.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.

317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
357	Revue	Cano SM, Montoro JB, Pastor C, Pou L, Sabin P. Stability of ranitidine hydrochloride in total nutrient admixtures. Am J Hosp Pharm 1988 ; 45: 1100-1102.
358	Revue	Lampasona V, Mullins RE, Parks RB. Stability of ranitidine admixtures frozen and refrigerated in minibags. Am J Hosp Pharm 1986 ; 43: 921-925.
359	Revue	Bullock LS, Parks RB, Lampasona V, Mullins RE. Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions. Am J Hosp Pharm 1985 ; 42: 2683-2687.
360	Revue	Inagaki K, Gill MA, Okamoto MP, Takagi J. Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 2769-2772.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
396	Revue	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
406	Revue	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
465	Revue	Wohlford JG, Wright JC, Wilson MR. More information on the visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1990 ; 47: 297-298.



472	Revue	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
689	Revue	Walker SE, Kirby K. Stability of ranitidine hydrochloride admixtures refrigerated in polyvinyl chloride minibags. Can J Hosp Pharm 1988 ; 41: 105-108.
693	Revue	Das Gupta V, Parasrampur J, Bethea C. Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures. J Clin Pharm Ther 1988 ; 13: 329-334.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
903	Revue	Inagaki K, Gill MA, Okamoto MP, Takagi J. Chemical compatibility of cefmetazole sodium with ranitidine hydrochloride during simulated Y-site administration. J Parenter Sci Technol 1993 ; 47: 35-39.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
934	Revue	Inagaki K, Kambara M, Mizuno M, Okuda J, Gill MA, Nishida M. Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated Y-site administration. Int J Pharm Compound 1998 ; 2: 318-321.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
958	Revue	Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M. Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion. Ann Pharmacotherapy 1990 ; 24: 440-442.
1067	Revue	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.

1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1248	Revue	Walker SE, Bayliff CD. Stability of ranitidine hydrochloride in total parenteral nutrient solution. Am J Hosp Pharm 1985 ; 42: 590-592.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1703	Revue	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten Arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1757	Revue	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.

1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1847	Revue	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1868	Revue	Husson E, Crauste-Manciet S, Hadj-Salah E, Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1888	Revue	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1900	Revue	Musami P, Stewart JT, Taylor EW. Stability of zidovudine and ranitidine in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23°C±2°C) and 4°C in 50 ml polyvinylchloride bags up to 24 hours. Int J Pharm Compound 2004 ; 8, 3: 236-239.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
1987	Revue	Oh J, Gwak H, Moon H, Choi I. Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations. Am J Health-Syst Pharm 2005 ; 62: 289-291.
2002	Revue	Abanmy NO, Zaghoul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.


2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2328	Laboratoire	Sugammadex (Bridion®) – Résumé des caractéristiques du produits Organon 2009
2355	Revue	Inagaki K, Miyamoto Y, Kurata N, Nakane S, Gill M.A, Nishida M. Stability of ranitidine hydrochloride with cefazolin sodium, cefbuperazone sodium, cefoxitin sodium nd cephalotin sodium during simulated Y-site administration. Int J Pharm Compound 2000 ; 4, 2: 150-153.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3558	Revue	Rowe H, Riley J, Newby B. Physical Compatibility of Ranitidine and Metoclopramide in 50-mL Minibags of Normal Saline. Can J Hosp Pharm 2013 ; 66, 5: 332.
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3637	Laboratoire	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015

3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilit� du citrate de caf�ine injectable avec plusieurs autres m�dicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4131	Revue	Fleming K, Donnelly R. Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine. Hosp Pharm 2019 ;54,1:32-36.
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Sch�rer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4428	Revue	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4470	Revue	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vall�e M, Barth�l�my I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.

# Stabilis



## Ranitidine hydrochloride



### Stabilité des préparations

		2.5 g Ranitidine HCl	Eau purifiée >> 100 ml	15-25°C		153		1927
		5 g Ranitidine HCl	Eau purifiée >> 100 ml	15-25°C		139		1927
		1500 mg Ranitidine HCl	Orablend® >> 100 mL	2-6°C		27		3336
		1500 mg Ranitidine HCl	Orablend® >> 100 mL	23-27°C		5		3336
		2.5 g Ranitidine HCl	Eau purifiée >> 100 ml	4°C		139		1927
		1449 mg ® = ?	SyrSpend SF PH4® >> 100 mL	2-8°C		58		3810
		1449 mg ® = ?	SyrSpend SF PH4® >> 100 mL	25°C		36		3810
		900 mg ®=? (Glaxo)	Eau distillée >> 180 ml Sirop simple >> 360 ml	25°C		7		2490



### Bibliographie

	Type	Source
1927	Revue	Ferreira MO, Bahia MF, Costa P. Stability of ranitidine hydrochloride in different aqueous solutions. EJHP 2004 ; 4: 60-63.
2490	Revue	Karnes HT, Harris SR, Garnett WR, March C. Concentration uniformity of extemporaneously prepared ranitidine suspension Am J Hosp Pharm 1989 ; 46: 304-307.
3336	Revue	Petit-Jean E, Perello L, Hernandez C, Gairard Dory A.C, Gourieux B, Ubeaud-Sequier G. Stability of an oral ranitidine suspension (15 mg/ml). EJHP 2013 ;20:46-49
3810	Revue	Geiger C M, Sorenson B, Whaley P. Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF. Int J Pharm Compound 2015 ; 19, 5 : 420-427.





# Dictionnaire

 Antihistaminique H2	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau ppi + bactériostatique	 A l'abri de la lumière
 Jour	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Lumière
 Non précisée	 Glucose 10%
 Polyéthylène	 Heure
 Seringue polypropylène	 Chlorure de sodium 0,9%
 Avec ou sans lumière	 Stabilité en mélange
 Solvant	 Molécule
 Non précisé	 Glucose 5%
 Compatibilités	 Compatible
 Précipitation immédiate	 Incompatible
 Aucun	 Instabilité chimique
 RL Ringer lactate	 NaCl 0,9% + bactériostatique
 Incompatibilité non précisée	 Eau pour préparation injectable
 Solvant spécifique	 Nutrition parentérale (mélange binaire)
 Turbidité immédiate	 Nutrition parentérale (mélange ternaire)
 Précipitation en 4 heures	 Instabilité de l'émulsion à 6 heures
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Intramusculaire
 Sous cutanée	 Perfusion SC continue
 Bibliographie	 Solution buvable
 Stabilité des préparations	 Origine
 Excipient	 Poudre



Flacon plastique



Comprimés



Dictionnaire